Indication: For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
Pharmacology: Benzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism Of Action: Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.
Drug Category: Adrenergic Agents; Dopamine Agents; Central Nervous System Agents; ATC:A08AA
Absorption: Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Interactions:
DrugBank: Interactions for Benzphetamine
Interactions for Benzphetamine:
Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following
use of monoamine oxidase inhibitors. DIDREX should not be used concomitantly with other CNS stimulants.
Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of
tricyclic antidepressants.
Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying
agents decrease blood levels and increase excretion of amphetamines.
Chemical IUPAC Name: N-benzyl-N-methyl-1-phenyl-propan-2-amine
Chemical Formula: C17H21N
Half Life: 16 to 31 hours
Drug Type: Approved Drug
# Accession No: APRD00759
CAS Registry Number: 156-08-1
Benzphetamine News (When available)
Pair living in FEMA trailer among 3 arrested in drug caseDec 12, 2005 2theadvocate.com, ...were each booked with possession with intent to distribute crack cocaine, possession with intent to distribute cocaine, possession of Didrex, and possession of ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
